Atossa Therapeutics, Inc. (ATOS)
| Market Cap | 41.16M -62.2% |
| Revenue (ttm) | n/a |
| Net Income | -37.64M |
| EPS | -4.37 |
| Shares Out | 8.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,445 |
| Open | 4.850 |
| Previous Close | 4.850 |
| Day's Range | 4.700 - 4.950 |
| 52-Week Range | 3.760 - 19.350 |
| Beta | 1.25 |
| Analysts | Strong Buy |
| Price Target | 22.75 (+375.94%) |
| Earnings Date | May 8, 2026 |
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ATOS stock is "Strong Buy." The 12-month stock price target is $22.75, which is an increase of 375.94% from the latest price.
News
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026 /PRNewswire/...
Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year
“During the quarter, we made meaningful progress advancing our (Z)-endoxifen development strategy across both oncology and rare disease indications,” stated Dr. Steven Quay, M.D., Ph.D., Atossa Therap...
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas...
Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial
Atossa Therapeutics (ATOS) announced the publication of results from the KARISMA Endoxifen trial in the Journal of the National Cancer Institute. The Phase 2 study evaluated daily oral Endoxifen and…
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer risk prevention candidate by marked reduction of mammographic breast density (MBD) Doses of both 1 mg...
Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS
Atossa Therapeutics (ATOS) announced that the U.S. FDA has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome in females. RPD designation is gran...
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- Atossa Ther...
Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Atossa Therapeutics (ATOS) to $25 from $7 and keeps a Buy rating on the shares. The firm cites the company’s 1-for-15 reverse…
Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)
2024 EPS was ($3.04). “While we have consistently made meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology over the last 12 months, we continue to explore the…
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other ar...
Atossa Therapeutics announces addition of two biopharma executives to team
Atossa Therapeutics (ATOS) announces the engagement of Kathy Puyana Theall, M.D., as Medical Director – Breast Oncology, and Adebola Giwa, M.D., as Medical Director – Rare Diseases. The addition of…
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasda...
Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Atossa Therapeutics (ATOS) to $10 from $35 and keeps a Buy rating on the shares. The firm cites Atossa’s decision to pause Z-endoxifen’s…
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other...
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Na...
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, Jan. 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" o...
Atossa Therapeutics: FDA grants orphan designation to (Z)-endoxifen
Atossa Therapeutics (ATOS) announced that the U.S. FDA Office of Orphan Products Development has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. Publ...
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, Jan. 16, 2026 /PRNewswire/ -- At...
FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen
Atossa Therapeutics (ATOS)’ (Z)-endoxifen was granted FDA orphan designation as a treatment of Duchenne muscular dystrophy, according to a post to the agency’s website.
Atossa Therapeutics receives “Study May Proceed” letter for breast cancer study
Atossa Therapeutics (ATOS) announced that the U.S. FDA issued a “Study May Proceed” letter for the company’s study in metastatic breast cancer which was the subject of a recent investigational…
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that...
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease Settings SEATTLE , Dec. 17, 2025 /PRNewswire/ -- Atossa T...
Atossa Therapeutics presents four trial updates on Z-endoxifen
Atossa Therapeutics (ATOS) presented four clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium, SABCS, held December 9-12, 2025, in San Antonio, TX. Presentation Highligh...
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reduction SEATTLE , Dec. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq:...